Gilead Sciences, Humana, Danaher, Medtronic, and McKesson are the five Medical stocks to watch today, according to MarketBeat's stock screener tool. Medical stocks are shares of companies that develop, produce, or provide medical and healthcare products and services, such as pharmaceuticals, medical devices, diagnostics, and healthcare services. Investors may consider them part of the broader healthcare sector, though their risks and performance vary by company and industry. These companies had the highest dollar trading volume of any Medical stocks within the last several days.
Gilead Sciences (GILD)
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.
Shares of Gilead Sciences stock traded up $1.96 during trading on Friday, reaching $168.49. The company's stock had a trading volume of 2,121,427 shares, compared to its average volume of 6,750,926. The firm has a market cap of $208.98 billion, a PE ratio of -53.26 and a beta of 0.35. Gilead Sciences has a fifty-two week low of $116.88 and a fifty-two week high of $176.58. The company has a 50-day moving average price of $156.80 and a two-hundred day moving average price of $142.34. The company has a current ratio of 1.38, a quick ratio of 1.22 and a debt-to-equity ratio of 1.84.
Read Our Latest Research Report on GILD
Humana (HUM)
Humana Inc., together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.
NYSE:HUM traded up $15.65 during mid-day trading on Friday, hitting $395.65. 865,203 shares of the company's stock traded hands, compared to its average volume of 1,660,915. Humana has a 1 year low of $163.11 and a 1 year high of $462.87. The company has a market cap of $47.52 billion, a PE ratio of 38.49, a price-to-earnings-growth ratio of 1.84 and a beta of 0.65. The firm's 50 day simple moving average is $409.87 and its 200 day simple moving average is $321.41. The company has a debt-to-equity ratio of 0.61, a quick ratio of 1.65 and a current ratio of 1.65.
Read Our Latest Research Report on HUM
Danaher (DHR)
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.
Shares of NYSE:DHR traded down $5.33 during trading on Friday, reaching $222.23. 1,490,207 shares of the stock were exchanged, compared to its average volume of 4,396,986. The firm has a market cap of $156.34 billion, a price-to-earnings ratio of 36.35, a price-to-earnings-growth ratio of 2.87 and a beta of 0.76. Danaher has a 12-month low of $160.93 and a 12-month high of $242.80. The company has a debt-to-equity ratio of 0.45, a quick ratio of 1.29 and a current ratio of 1.63. The firm's 50-day moving average price is $224.42 and its 200 day moving average price is $201.64.
Read Our Latest Research Report on DHR
Medtronic (MDT)
Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.
Shares of NYSE:MDT traded up $0.32 during trading on Friday, hitting $100.93. 2,536,733 shares of the company traded hands, compared to its average volume of 11,054,338. The business's fifty day moving average is $94.44 and its 200-day moving average is $88.47. The stock has a market capitalization of $129.11 billion, a price-to-earnings ratio of 24.85, a PEG ratio of 2.36 and a beta of 0.56. The company has a quick ratio of 1.54, a current ratio of 2.07 and a debt-to-equity ratio of 0.50. Medtronic has a one year low of $73.31 and a one year high of $106.33.
Read Our Latest Research Report on MDT
McKesson (MCK)
McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products.
Shares of McKesson stock traded up $19.73 during midday trading on Friday, hitting $1,081.89. The company's stock had a trading volume of 225,579 shares, compared to its average volume of 904,296. The firm has a market capitalization of $124.92 billion, a P/E ratio of 27.87, a PEG ratio of 1.84 and a beta of 0.27. The stock has a 50-day simple moving average of $970.87 and a 200-day simple moving average of $879.62. McKesson has a 1-year low of $723.68 and a 1-year high of $1,121.50.
Read Our Latest Research Report on MCK
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Gilead Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Gilead Sciences wasn't on the list.
While Gilead Sciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.
This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.